Presentation | Objectives | Research Activities | Participants | The team | EuroBoNeT Management Structure

Leiden University Medical Center, Leiden, The Netherlands

Prof Pancras CW Hogendoorn (MD, PhD)
Scientific Network Coordinator
Coordinator for LUMC
Research line leader of RL1
Work package leader of WP1.2
Professor in pathology specialised in the pathology of bone and soft tissue tumours and head of the bone tumour research group. The main emphasis of his research is focussed on cartilage tumours, osteosarcomas and Ewing sarcomas.

Judith VMG Bovee (MD, PhD)
Work package leader of WP1.1
Pathologist specialised in the pathology of bone and soft tissue tumours. She is part of the bone tumour research group. The main emphasis of her research is focussed on enchondromas, osteochondromas and chondrosarcomas.

Anne Marie Cleton-Jansen (PhD)
Leader of the technology platforms
Biologist, working in the bone tumour research group and molecular tumour genetics group. The main emphasis of her research is focussed on osteosarcomas and cartilaginous tumours

Arjan C Lankester (MD, PhD)
Work package leader of WP4.2
Pediatrician-immunologist and program director Stem Cell Transplantation

Prof Dick P Engberts (PhD)
Head of ethics committee
Professor in Normative Aspects of Medicine.
Leida Rozeman (PhD)
Assistant coordinator
Biologist, background in chondrosarcoma research.

Pauline de Graaf
Master’s degree in English literature

Ph.D. students
Yongping Cai
Twinkal Pansuriya
Alex Mohseny

Multiple Osteochondromas
Christianne Reijnders
Istituti Ortopedici Rizzoli, Bologna, Italy

Marco Alberghini (MD)
Director of Pathology Department of the Rizzoli Orthopaedic Institute
Specialized in Bone and soft tissue pathology

Dr.Alberghini is :member of Italian  Sarcoma Group
 member of  International Skeletal Society

The main interests of pathology department of the Rizzoli Institute are bone and soft tissue tumors, and collaborations with the research groups in the study of these entities, from a retrospective and prospectic point, with the aim of identify new therapies with immunohistochemistry , molecular biology and biobanking activity.

Piero Picci (MD, PhD)
Research line leader of RL4
Coordinator for IOR
He has been the Director of the Laboratory of Oncologic Research since1994. Furthermore, he has been the Scientific Director of the Istituti Ortopedici Rizzoli since 2004.

• In addition Dr. Picci is:
- President of the Italian Sarcoma Group
- Ex-President of the European Musculoskeletal Oncology Society
- Member of the Board of Directors of the SARC Foundation

The Istituti Ortopedici Rizzoli is the main Italian centre for the study and the treatment of primary bone tumours. The vast majority of bone sarcomas diagnosed in Italy are treated at the Istituti Ortopedici Rizzoli. The four Research Units of the Laboratory of Oncologic Research are devoted to the following research areas:
• Biomolecular studies
• Genetics
• Growth factors and receptors
• Drug resistance

Dr. Katia Scotlandi
Work package leader of WP4.3
Katia Scotlandi is the Chief of the Operative Unit “Growth Factor and Receptors”, Laboratory of Oncologic Research. She is devoted to the study of sarcomas since the time of graduation and she has been working in Rizzoli Institute since 1994. The unit "Growth factors and receptors" research activity:
• preclinical studies on the development of targeted therapies for sarcomas with particular emphasis on the antimetastatic effects;
• biomolecolar analysis of the Ewing’s sarcoma;
• evaluation of the biological role of the CD99 molecule and Identification of its intracellular signaling pathways;
• genetic profile of sarcomas by Real Time quantitative PCR e cDNA microarray technologies;
• identification of new therapeutic targets crucial for the pathogenesis and tumor progression of bone affecting tumors

Dr. Massimo Serra
Work package leader of WP2.2
He is the Responsible for the Research Unit “Studies on drug resistance in musculoskeletal tumors” of the Laboratory of Oncologic Research. This Research Unit is focused on the identification of genetic and molecular bases responsible for the reduced sensitivity to chemotherapeutic drug in the most common musculoskeletal tumors, with particular regard to osteosarcoma. In particular, the most relevant investigation fields of this Research Unit are:
• analysis of genetic and molecular mechanisms responsible for resistance to doxorubicin, methotrexate and cisplatin in human osteosarcoma cells;
• preclinical assessment of the efficacy of new antitumour agents and of their interactions with conventional chemotherapeutic drugs;
• pharmacogenomic and pharmacogenetic characterisation of the most common musculoskeletal tumours, with particular regard to osteosarcoma.

Dr. Luca Sangiorgi
He is in charge of the Genetic Unit of IOR. The Rizzoli’s Genetic Unit collaborates with various regional, national and international projects, on studies and research that deal with skeletal genetic diseases. Some of them are:
• Italian Registry of Exostosis Disease
• Gene Expression Profiling in Osteosarcoma: An NIH/Rizzoli Institute Joint Study
• European Skeletal Displasia Network (ESDN)
• GeBBALab PROJECT financed by PRRIITT (Regional program for industrial research, innovation and technological transfer of Emilia-Romagna Region Programma Regionale per la Ricerca Industriale, l'Innovazione e il Trasferimento Tecnologico della Regione Emilia-Romagna)
• Virtual Technological Park on Genetics and Health Biotechnologics in Emilia-Romagna

Dr. Maria Serena Benassi
Since 1989 Biologist Researcher of the Laboratory of Oncologic Research - Istituti Ortopedici Rizzoli. Responsible for the Research Unit “Biomolecular Studies on Musculoskeletal Tumors”. Research activity is focused on molecular characterization of musculoskeletal sarcomas to associate molecular defects to different histological subtypes with different grades of malignancy. This is certainly useful for clinical purposes to improve prognosis and monitor treatment. In particular, this research unit is thus subdivided:
• identification and characterization of genes implicated in pathogenesis and malignant progression of sarcomas in order to correlate structural and functional alterations with the clinical aspects of the disease so as to recognize new prognostic factors;
• molecular classification of soft tissue sarcomas to biologically differentiate histotypes according to molecular defects
• Protein profile analyses of tissues and plasma to reveal within cellular processes deregulated pathways which represent “targets” for an aimed therapy;
• characterization of sarcoma cell lines and evaluation of biological response to compounds that sensitize tumor cells to conventional treatments.

Prof. Andrea Facchini
Prof. Andrea Facchini is the Director of the Laboratory of Immunology and genetics. From 1983 to 2001 he was Associate Professor Clinical Immunology, and since 2001 he is Full Professor of Internal Medicine, Clinical Immunology and Allergology at the School of Medicine of the University of Bologna. He has been Director of the Laboratory of Immunology and Genetics of IOR since 1987 (Medical area, Branch of Allergology and Clinical Immunology) and Vice-Scientific Director since 1999.
The Laboratory of Immunology and Genetics was set up at Rizzoli Orthopaedic Institute in 1989. It obtains funds from Italian Health Ministry, MIUR, Bologna University and European Union. Since its establishment, the main research fields of the group have been
• the study of pathogenetic mechanisms of different rheumatic diseases,
• the development of innovative orthopaedic treatments, such as tissue engineering
• and the analysis of physiopathological modifications of the immune system during ageing.

Dr. Andrea Rizzi
Administrative collaborator for IOR. He takes care of the administrative and financial problems related to European projects and the Scientific Direction of the Rizzoli institute.

Helsinki University Central Hospital, Helsinki, Finland

Prof Sakari Knuutila
Coordinator for HUCH
Head of the Cytomolecular
Genetics Laboratory
N Goormaghtig institute of pathology, Gent, Belgium

Dr. Ramses George Forsyth
Work package leader of WP3.1
Technical platform leader of TP5.4
Pathologist - Staff member, specialised in (diagnostic) molecular techniques and pathology of bone and soft tissue tumours. The main emphasis is focused on giant cell containing bone tumours. Other topics include tendon healing and cartilage tissue engineering.
University of Antwerp, Antwerp, Belgium

Prof Wim van Hul (MD, PhD)
Coordinator for UA
Work package leader of WP3.3

Wim Wuyts (PhD)
Work package leader of WP1.3
University College London, London, UK

  Adrienne M. Flanagan (PhD)
Professor of Musculoskeletal Pathology
Coordinator for UCL
Universitat de Valencia studi General, Valencia, Spain

Prof Antonio Llombart Bosch (MD, PhD)
Coordinator for UVEG
Heinrich-Heine-University Dűsseldorf, Dűsseldorf, Germany

Prof Christopher Poremba (MD, PhD)
Coordinator for HHU Dűsseldorf
Institute of Pathology, University of Bern, Bern, Switzerland

  Pierre Mainil-Varlet (MD PhD)
Coordinator for UBern-OARG
Work package leader of WP1.4
His main research interest is focused on tissue engineering of bone and cartilage and cartilage tumour biology.
Nuffield Department of Orthopaedic Surgery, Oxford, United Kingdom

  Prof Nicholas A Athanasou (MD PhD)
Coordinator for UOXF.HF
Research line leader of RL3
Work package leader of WP3.2
CIC Salamanca, Salamamca, Spain

Enrique De Álava (MD, PhD)
Coordination for CIC Salamanca
Work package leader of WP4.1
Norwegian Radium Hospital, Oslo, Norway

Prof Ola Myklebost (PhD)
Coordinator for Radium Hosprital
Work package leader of WP2.1
Lund University, Lund, Sweden

Prof Fredrik Mertens (MD, PhD)
Coordinator for ULUND
Work Package leader of WP2.3

Thor A Alvegård (MD PhD)
Universität Leipzig, Leipzig, Germany

Professor Dr. Thomas Aigner (MD, DSc, BPh)
Coordinator for Leipzig
Professor of Oncological Pathology, Vice-Director of the Department of Pathology and Head of Molecular Pathology of the University Leipzig, Germany. The main emphasis of his work is mortality, degeneration and immortality of chondrocytes as well as functional genomics and systems biology of the skeletal tissues.

University of Leuven, Leuven, Belgium

Prof Raf Sciot (MD, PhD)
Coordinator for KULeuven

Maria Debiec-Rychter (MD, PhD)

Esther Hauben, PhD
Westfälische Wilhelmsuniversität Münster, Münster, Germany

Prof Horst Bűrger (MD, PhD)
Coordinator for WWU Münster
Research line leader of RL2
Pathologist and Molecular Pathologist - Focus on tumour progression pathways.

Dr. Eberhard Korsching (PhD)
Platform leader bioinformatics
Biochemist and theoretical biologist - Research interests in biological networks, analysis concepts for complex systems and array technologies. Member of the tumour research group.

Dr. Konstantin Agelopoulos (PhD)
Research line 2.2
Biologist - Field of activity: Tumour genetics. Focus on EGFR in osteosarcomas Genetics, transcriptional regulation and pathway activation.

Dr. Hartmut Schmidt (PhD)
Research line 2.2
Biologist - Diagnostic methods in molecular biology.

Ronaldo Schuch (PhD student)
Research line2.2
Biochemist - Research interests in transcription factors around EGFR regulation.

Anna Neumann (PhD student)
Research line2.2
Biologist - Research interests in metastasis of osteosarcomas.

Dr. Maurice Balke (MD)
Research line 3.1
Orthopedic surgeon - Department of Orthopedic Surgery
Hospital of Treviso, Treviso, Italy

Prof Angelo Paolo Dei Tos (MD, PhD)
Coordinator for Treviso Hospital
Network manager of "integrating activities" and "spreading of excellence"
Work package leader of WP5.1
Semmelweis University, Budapest, Hongary

Prof Miklós Szendrõi (MD, PhD)
Coordinator for Semmelweis
Prof László Kopper (MD, PhD)
Head of the 1st Pathological Institution of Semmelweis
Stiftung Orthopädische Universitätsklinik Heidelberg, Heidelberg, Germany

Prof Wiltrud Richter (PhD)
Coordinator for Ortho Heidelberg.
Professor in experimental orthopaedics specialised in cell and molecular biology of musculoskeletal tissues. The main emphasis of her research is focussed on mesenchymal stem cell development, cartilage biology and tissue engineering. The oncology research group within the division of experimental orthopaedics investigates the biology and genetics of bone and cartilage tumours, clinical outcome of treatment of bone tumours and quality of life in orthopaedic oncology.

Pepscan Systems BV, Lelystad, The Netherlands

Jos Joore (PhD)
Coordinator for Pepscan

MRC-Holland, Amsterdam The Netherlands

Jan P Schouten (PhD)
Coordinator for MRCH

SOLVO Biotechnology Inc, Budapest, Hungary
H-6722 Szeged, Béke u. 5/a, Tel. +36-23-503-940, Fax: +36-23-503- 941, Mobile: +36-30-639-2133, Email

Zsolt Holló (MD, PhD)
Medical Director & Chief Operations Officer
Zsolt Holló is a founder and an active member of Solvo's Board of Directors since 1999. He has joined Solvo in 2004 as a Medical Director and by 2005 he was appointed as Chief Operations Officer. Dr. Holló has more than 7 years of experience in basic and applied research of multidrug resistance proteins. Previously the founder and Managing Director of Genodia Molecular Diagnostic Ltd. (2001-2003), a major Hungarian molecular diagnostic laboratory company. He was the Head of Genetic Division at H-Med Diagnostic Ltd., Budapest (1999-2001). He was a postdoctoral research fellow at the Division of Molecular Biology, Netherlands Cancer Institute, Amsterdam (1997-1999), supported by an EMBO Long Term Fellowship. Between 1999-1997 he worked as a research fellow at the Department of Cell Metabolism, National Institute of Hematology and Immunology, Budapest. Dr. Holló obtained his Ph.D. degree in Molecular and Cellular Physiology in 1999 and his Medical Degree from the Semmelweis University Medical School, Budapest in 1990.
Erasmus Medical Center, Rotterdam, The Netherlands

Peter Riegman (PhD)
Coordinator for Eramus MC
Work-package leader of WP5.3
Coordinator of the virtual BioBank
Wahid Hamidi
for the EuroBoneT biobank application